Evidence map›Paper›PMID 39133306›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2025

Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine.

Solfrid Thunold, Eivor Hernes, Saima Farooqi, Åsa Kristina Öjlert, Roslyn J Francis, Anna K Nowak, Weronika Maria Szejniuk, Søren Steen Nielsen, Susana Cedres, Marc Simo Perdigo and 6 more

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04300244 (Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04300244 phase2active not recruitingnot on this map

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (the NIPU-study)

TypeinterventionalSponsorÅslaug HellandRan2020 to 2027Enrolled118ConditionsCancer, Cancer, Lung, Cancer of Lung, MesotheliomaArmsUV1 vaccine + leukine, ipilimumab, nivolumab
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Dual-time-point [EJNMMI research · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Solfrid ThunoldDept of Oncology, Oslo University Hospital, Oslo, Norway. solthu@ous-hf.no.ORCID 0009-0004-9277-7796
Eivor HernesDivision of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Saima FarooqiDept of Oncology, Oslo University Hospital, Oslo, Norway.
Åsa Kristina ÖjlertDept of Oncology, Oslo University Hospital, Oslo, Norway.
Roslyn J FrancisDept of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, Australia.
Anna K NowakMedical School of The University of Western Australia, Perth, Australia.
Weronika Maria SzejniukClinical Cancer Research Center & Department of Oncology, Aalborg University Hospital, Aalborg, Denmark.
Søren Steen NielsenDepartment of Nuclear Medicine, Aalborg University Hospital, Aalborg, Denmark.
Susana CedresVall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Marc Simo PerdigoDept of Nuclear Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Jens Benn SørensenDepartment of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Carin MeltzerDivision of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Lars Tore Gyland MikalsenDepartment of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Åslaug HellandDept of Oncology, Oslo University Hospital, Oslo, Norway.
Eirik MalinenDept of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Vilde Drageset HaakensenDept of Oncology, Oslo University Hospital, Oslo, Norway.

Funding

Helse Sør-Øst RHF 2020077Helse Sør-Øst RHF 2021083
6 · The paper itself

Abstract

purposeThe introduction of immunotherapy in pleural mesothelioma (PM) has highlighted the need for effective outcome predictors. This study explores the role of [18F]FDG PET/CT in predicting outcomes in PM treated with immunotherapy.

methodsPatients from the NIPU trial, receiving ipilimumab and nivolumab +/- telomerase vaccine in second-line, were included. [18F]FDG PET/CT was obtained at baseline (n = 100) and at week-5 (n = 76). Metabolic tumour volume (MTV) and peak standardised uptake value (SUV

resultsUnivariate Cox regression revealed significant associations of MTV with OS (HR 1.36, CI: 1.14, 1.62, p < 0.001) and PFS (HR 1.18, CI: 1.03, 1.34, p = 0.02), while multivariate analysis showed a significant association with OS only (HR 1.35, CI: 1.09, 1.68, p = 0.007). While SUV

conclusionMTV provides prognostic value in PM treated with immunotherapy. High SUV STUDY REGISTRATION: The NIPU trial (NCT04300244) is registered at clinicaltrials.gov. https://classic. CLINICALTRIALS: gov/ct2/show/NCT04300244?cond=Pleural+Mesothelioma&cntry=NO&draw=2&rank=4.

Indexed as

Cancer VaccinesFluorodeoxyglucose F18IpilimumabMesotheliomaNivolumabPleural NeoplasmsPositron Emission Tomography Computed TomographyTelomeraseAgedAged, 80 and overFemaleHumansMaleMesothelioma, MalignantMiddle AgedTreatment OutcomeCancer VaccinesFluorodeoxyglucose F18IpilimumabNivolumabTelomerase[18F]FDG PETImmunotherapyMTVPleural mesotheliomaSUVTelomerase vaccine

Identifiers

PMID39133306
PMCPMC11732904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.